Clinical Trials Directory

Trials / Completed

CompletedNCT00327392

A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.

A Phase 3 Open-Label, Single Arm Study to Assess the Safety of AQUAVAN® (Fospropofol Disodium) Injection for Minimal-to-Moderate Sedation in Patients Undergoing Minor Surgical Procedures

Status
Completed
Phase
Phase 2 / Phase 3
Study type
Interventional
Enrollment
123 (actual)
Sponsor
Eisai Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Very often patients receive medications before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. With respect to minimal-to-moderate procedural sedation for minor surgical procedures, a patient is first given a pain-relief medication (analgesic) and then a medication to help him/her relax and keep calm (sedative). AQUAVAN is a chemically modified form of propofol, a commonly-used sedative drug. AQUAVAN acts like a slow release version of propofol, and is being studied to see if it can safely keep patients calm and relaxed during their medical procedure and then allow for rapid and clear-headed recovery.

Detailed description

This is a Phase 3 open-label, single-arm study designed to evaluate the safety of AQUAVAN following pretreatment with an analgesic, fentanyl, in patients who are undergoing minor surgical procedures that require minimal-to-moderate sedation. All patients will be placed on supplemental oxygen via nasal cannula and an electrocardiogram monitor, pulse oximeter, and blood pressure monitor will be attached prior to administration of fentanyl. Assessments will be made to evaluate the safety of AQUAVAN in patients undergoing minor surgical procedures.

Conditions

Interventions

TypeNameDescription
DRUGAQUAVAN® (fospropofol disodium) Injection

Timeline

Start date
2006-05-01
Completion
2007-12-01
First posted
2006-05-18
Last updated
2012-06-20
Results posted
2012-06-20

Locations

15 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00327392. Inclusion in this directory is not an endorsement.